The world’s first antibacterial copper-containing titanium alloy bone pin, jointly developed by the Institute of Metal Research, Chinese Academy of Sciences, and Suzhou Senfeng Medical Device Co., Ltd., has received regulatory approval from China’s National Medical Products Administration. The device, officially granted a medical device registration certificate on April 21, marks a significant breakthrough in transforming conventional bio-inert medical metals into bioactive implants.
Titanium alloys are widely used in orthopaedic and dental implants because of their excellent mechanical properties and biocompatibility. Titanium alloy bone pins are among the most commonly employed devices for fracture fixation. However, implant-associated infections remain a serious clinical challenge. Biofilm formation on conventional inert metal surfaces often leads to refractory infections, prolonged antibiotic therapy, and even revision surgeries.
To address this critical issue, research teams led by Prof. YANG Ke and Prof. REN Ling proposed an innovative “biofunctionalization of medical metallic materials” strategy as early as 2013. They subsequently developed a novel copper-containing titanium alloy, Ti6Al4V5Cu, which harnesses the intrinsic antibacterial activity of copper ions. The alloy not only exhibits excellent anti-infective properties and good biosafety, but also outperforms the clinically dominant Ti6Al4V alloy in mechanical strength, hardness and fatigue resistance, thereby further enhancing the safety of bone pin implants.
Through years of systematic research, the team has published more than 60 papers in journals such as Journal of Materials Science & Technology, Bioactive Materials and Nature Communications, obtained over 40 invention patents, and released three relevant group standards. Mature processing techniques for plates, bars and wires of the copper-containing titanium alloy have been established, enabling large-scale production and providing a solid material foundation for clinical translation.
Working closely with Suzhou Senfeng Medical Device Co., the IMR team participated in the entire product development and registration process, including comprehensive physiochemical and biological evaluations, large-animal studies and clinical trials, all conducted in strict compliance with medical device regulations.
The approval of this first-of-its-kind copper-containing titanium alloy orthopaedic implant represents a successful transition from fundamental research to clinical application. It embodies a paradigm shift from bio inert to bio functional medical metal design, placing China at the forefront of this field, and demonstrates a complete innovation chain from basic science and scalable material production to clinical deployment.
